Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis |
| Type de publication | Journal Article |
| Year of Publication | 2014 |
| Auteurs | Robin M, Giannotti F, Deconinck E, Mohty M, Michallet M, Sanz G, Chevallier P, Cahn J-Y, Legrand F, Rovira M, Passweg J, Sierra J, Nguyen S, Maillard N, Yakoub-Agha I, Linkesch W, Cannell P, Marcatti M, Bay J-O, Chalandon Y, Kroger N, Gluckman E, Rocha V, Olavarria E, Ruggeri A, Work EChronic Ma |
| Journal | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION |
| Volume | 20 |
| Pagination | 1841-1846 |
| Date Published | NOV |
| Type of Article | Article |
| ISSN | 1083-8791 |
| Mots-clés | Myelofibrosis, Umbilical cord blood transplantation |
| Résumé | {To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0% |
| DOI | 10.1016/j.bbmt.2014.06.011 |